# Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes

> **NCT05689684** · NA · COMPLETED · sponsor: **Lund University** · enrollment: 66 (actual)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DIETARY_SUPPLEMENT:** AG+XOS+AXOS
- **DIETARY_SUPPLEMENT:** Placebo Maltodextrin

## Key facts

- **NCT ID:** NCT05689684
- **Lead sponsor:** Lund University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-07
- **Primary completion:** 2023-10-06
- **Final completion:** 2024-12-31
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05689684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05689684, "Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05689684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*